Answers are grounded in this paper and cite their sources.
Since the number of patients seen in a pediatric oncology center is relatively small, it is difficult to perform single drug phase two studies, even on a national base. This also probably explains the lack of information on ifosfamide, despite the fact that it has now been used for more than 10 years in pediatrics. As long as chemotherapy plays such an important role in childhood cancer it remains of the utmost importance to determine the role of ifosfamide in the treatment of young cancer patients.
No takes yet. Share an insight, caveat, or question.
Jan de Kraker (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: